Why did reported earnings decline even though sales grew 25%?

Reported net earnings available to common shares fell to $33.9 million from $39.3 million because of $35.9 million in one-time Whitmire merger costs and a higher effective tax rate of 50.3%, driven partly by nondeductible merger expenses. Excluding these unusual items, pro forma earnings were $63.0 million, or $1.60 per share, suggesting the underlying business grew.

What is the impact of the Whitmire merger on the company?

The February 1994 pooling-of-interests merger with Whitmire Distribution combined the company with a western and central U.S. distributor, expanding national reach and customer coverage. Costs included roughly $7 million in transaction fees, $13 million in restructuring, $6 million for systems integration, and $2 million for debt restructuring, with $11.7 million incurred by June 30, 1994.

Is the company's balance sheet and liquidity healthy?

Yes. Equity rose to $368.5 million, long-term debt declined to $210.1 million after the debenture conversion, and the company has $296 million of unused credit lines. However, operating cash flow was negative $74.9 million due to inventory and receivables build-up, so investors should monitor working capital needs.

What are the main risks investors should consider?

Key risks include thin margins in a highly competitive wholesale market, pressure from consolidating customers and manufacturers, dependence on a few large suppliers (the top five accounted for 29% of sales), exposure to healthcare reform legislation, and the pending antitrust class action over chargeback pricing. Gross margin compression is expected to continue, though at a slower pace.

What is the company's acquisition and capital-raising outlook?

The company continues to pursue acquisitions, completing Humiston-Keeling (July 1, 1994) and Behrens (July 18, 1994) shortly after year-end. It also filed for an underwritten offering of 5.25 million Class A shares, with 1.6 million sold by the company, to fund working capital growth and general corporate purposes. Management believes existing resources are adequate even without these proceeds.

CAH 10-K FY1994 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed September 2, 1994. Cited figures are marked; the original filing is the authoritative source.

Cardinal Health, Inc. (CAH) reported fiscal year ended June 30, 1994 (a transition period following its change from a March to June fiscal year-end) with net sales of $5.79 billion^a, up 25% from the prior twelve-month period, driven by roughly 20% internal growth plus the PRN and Solomons acquisitions.

Net earnings available to common shares were $33.9 million^b, or $0.86 per share, down from $39.3 million ($1.14) a year earlier, as the company absorbed $35.9 million in pre-tax Whitmire merger costs in the third quarter. Excluding these unusual items, pro forma operating earnings rose to $121.9 million and pro forma net earnings to $63.0 million ($1.60 per share), indicating underlying profitability held up well. Gross margin compressed to 6.13% from 6.42%, reflecting more competitive pricing and a higher mix of large-volume customers, though management expects the decline to moderate.

Results should be read with caution: the effective tax rate jumped to 50.3% due to nondeductible merger costs, and the company faces a pending antitrust class action over chargeback pricing. The balance sheet strengthened materially. Shareholders' equity rose to $368.5 million^c from $247.9 million, largely from the conversion of $75 million of convertible debentures into common shares.

Long-term debt fell to $210.1 million^d, and the company now has a $321 million line-of-credit capacity with $296 million unused. Working capital grew to $471.1 million, though inventories (up $233 million) and receivables absorbed substantial cash, producing negative operating cash flow of $74.9 million for the year. The company also has a pending public offering of 5.25 million Class A shares, of which 1.6 million are primary, and it continues an active acquisition program, having closed Humiston-Keeling and Behrens in July 1994.

02—Key points

Key Highlights

Net sales of $5.79 billion, up 25% year over year, with about 20% from internal business growth and the balance from acquisitions (PRN, Solomons).
Reported EPS of $0.86 versus $1.14 prior period, reflecting $35.9 million ($28.2 million after tax) in Whitmire merger costs; pro forma EPS excluding unusual items was $1.60.
Gross margin fell to 6.13% from 6.42% due to more competitive selling margins and a shift toward high-volume customers, with management expecting the decline to moderate.
Shareholders' equity nearly doubled? No: rose 49% to $368.5 million, driven mainly by the $74.9 million convertible debenture conversion, while long-term obligations fell to $210.1 million.
Operating cash flow was negative $74.9 million as inventories rose $232 million and receivables rose $85 million, consistent with seasonal purchasing and growth.
Liquidity is solid, with $296 million of unused bank credit lines and working capital of $471.1 million.
Pending litigation: wholesalers including Cardinal and Whitmire face purported class action antitrust suits over chargeback pricing, which the company calls without merit.

03—Questions

Frequently Asked Questions

Why did reported earnings decline even though sales grew 25%?
Reported net earnings available to common shares fell to $33.9 million from $39.3 million because of $35.9 million in one-time Whitmire merger costs and a higher effective tax rate of 50.3%, driven partly by nondeductible merger expenses. Excluding these unusual items, pro forma earnings were $63.0 million, or $1.60 per share, suggesting the underlying business grew.
What is the impact of the Whitmire merger on the company?
The February 1994 pooling-of-interests merger with Whitmire Distribution combined the company with a western and central U.S. distributor, expanding national reach and customer coverage. Costs included roughly $7 million in transaction fees, $13 million in restructuring, $6 million for systems integration, and $2 million for debt restructuring, with $11.7 million incurred by June 30, 1994.
Is the company's balance sheet and liquidity healthy?
Yes. Equity rose to $368.5 million, long-term debt declined to $210.1 million after the debenture conversion, and the company has $296 million of unused credit lines. However, operating cash flow was negative $74.9 million due to inventory and receivables build-up, so investors should monitor working capital needs.
What are the main risks investors should consider?
Key risks include thin margins in a highly competitive wholesale market, pressure from consolidating customers and manufacturers, dependence on a few large suppliers (the top five accounted for 29% of sales), exposure to healthcare reform legislation, and the pending antitrust class action over chargeback pricing. Gross margin compression is expected to continue, though at a slower pace.
What is the company's acquisition and capital-raising outlook?
The company continues to pursue acquisitions, completing Humiston-Keeling (July 1, 1994) and Behrens (July 18, 1994) shortly after year-end. It also filed for an underwritten offering of 5.25 million Class A shares, with 1.6 million sold by the company, to fund working capital growth and general corporate purposes. Management believes existing resources are adequate even without these proceeds.

04—Continue

← View all 10-K filings